Report Feature
The future of the global rare biomarker specimen collection and stabilization market looks promising with opportunities in the NIPT (Non Invasive Prenatal Testing), oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, and cardiovascular diseases. The global rare biomarker specimen collection and stabilization market is expected to grow with a CAGR of 10%-12% from 2020 to 2025. The major drivers for this market are increasing research activities for depicting the role of circulating biomarkers in disease management, and rising demand for non-invasive cancer diagnostic and personalized medicines.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global rare biomarker specimen collection and stabilization market report, please download the report brochure.
The study includes trends and forecast for the global rare biomarker specimen collection and stabilization market by product, type, specimen, nucleic acid and other biomolecules, application, end use, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
- Isolation Kits & Reagents
- Blood Collection Tubes
- Systems
By Type [Value ($ Million) shipment analysis for 2014 – 2025]:
- Circulating Call Free DNA (ccfDNA)
- Circulating Tumor Cells (CTCs)
- Exosomes/Extracellular Vesicles
By Specimen [Value ($ Million) shipment analysis for 2014 – 2025]:
- Serum/Plasma
- Others
By Nucleic Acid & Other Biomolecules [Value ($ Million) shipment analysis for 2014 – 2025]:
- RNA (Ribonucleic Acid)
- DNA (Deoxyribonucleic Acid)
- Others
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
- NIPT
- Oncology
- Transcriptomics
- Pharmacogenomics
- Transplant Rejection
- Population Screening
- Cardiovascular Diseases
- Others
By End Use [Value ($ Million) shipment analysis for 2014 – 2025]:
-
Research
- Research Labs/CROs
- Academic Institutes
-
Diagnostics
- Laboratories
- Hospitals
- Prenatal Clinic
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
-
North America
- United States
- Canada
- Mexico
-
Europe
- United Kingdom
- Germany
- France
-
Asia Pacific
- China
- India
- Japan
-
The Rest of the World
- Brazil
Some of the rare biomarker specimen collection and stabilization companies profiled in this report include Agena Bioscience, BioChain Institute, Epic Sciences, Biovision, Geno Technology, Roche, ANGLE, AS ONE International, Biolidics, Biomatrica, and Caltag Medsystems.
Within this market, research will remain the largest segment by end use over the forecast period due to increasing interest in rare biomarkers owing to their exclusive functions as intercellular messengers, their therapeutic potential in disease diagnostics, abilities to alter recipient cell bioactivities, and growing applications in drug delivery.
North America will remain the largest region over the forecast period due to the presence of a large number of clients and substantial number of FDA approved products such as isolation kits for both clinical use and research use due to rising liquid biopsy and assisted reproductive technology space in the region.
|
Features of the Global Rare Biomarker Specimen Collection and Stabilization Market |
|
|
This report answers following key questions |
|
Q.1 What are some of the most promising potential, high-growth opportunities for the global rare biomarker specimen collection and stabilization market by product (isolation kits & reagents, blood collection tubes, and systems), type (circulating call free DNA (ccfDNA), circulating tumor cells (CTCs), and exosomes/extracellular vesicles), specimen (serum/plasma and others), nucleic acid & other biomolecules (RNA, DNA, and others), application (NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases, and others), end use (research (research labs/CROs and academic institutes) and diagnostics (laboratories, hospitals and prenatal clinic)), and region (North America, Europe, Asia Pacific, and Rest of the World)? Q.2 Which segments will grow at a faster pace and why? Q.3 Which region will grow at a faster pace and why? Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global rare biomarker specimen collection and stabilization market? Q.5 What are the business risks and threats to the global rare biomarker specimen collection and stabilization market? Q.6 What are the emerging trends in this rare biomarker specimen collection and stabilization market and the reasons behind them? Q.7 What are some changing demands of customers in this rare biomarker specimen collection and stabilization market? Q.8 What are the new developments in this rare biomarker specimen collection and stabilization market? Which companies are leading these developments? Q.9 Who are the major players in this rare biomarker specimen collection and stabilization market? What strategic initiatives are being implemented by key players for business growth? Q.10 What are some of the competitive products and processes in this rare biomarker specimen collection and stabilization market, and how big of a threat do they pose for loss of market share via material or product substitution? Q.11 What M&A activities did take place in the last five years in the global rare biomarker specimen collection and stabilization market? |
Report Scope
| Key Features | Description |
| Base Year for Estimation | 2019 |
|
Trend Period (Actual Estimates) |
2014-2019 |
| Forecast Period | 2020-2025 |
| Pages | More than 150 |
| Market Representation / Units | Revenue in US $ Million |
| Report Coverage | Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling |
| Market Segments | Product (Isolation Kits & Reagents, Blood Collection Tubes, and Systems), Type (ccfDNA, CTCs, and Exosomes/Extracellular Vesicles), Specimen (Serum/Plasma and Others), Nucleic Acid & Other Biomolecules (RNA, DNA, and Others), Application (NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others), and End Use (Research (Research Labs/CROs and Academic Institutes) and Diagnostics (Laboratories, Hospitals and Prenatal Clinic)) |
Regional Scope |
North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil) |
| Customization | 10% Customization without Any Additional Cost |
Table of Contents
1. Executive Summary
7.2 Emerging Trends in the Global Rare Biomarker Specimen Collection and Stabilization Market
4.1 Global Rare Biomarker Specimen Collection and Stabilization Market by Region
4.2.1 Market by Product: Isolation Kits & Reagents, Blood Collection Tubes, and Systems
4.2.2 Market by Type: Circulating Call Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles
4.2.3 Market by Specimen: Serum/Plasma and Others
4.2.4 Market by Nucleic Acid & Other Biomolecules: RNA, DNA, and Others
4.2.5 Market by Application: NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others
4.2.6 Market by End Use: Research (Research Labs/CROs and Academic Institutes), Diagnostics (Laboratories, Hospitals, and Prenatal Clinic)
4.2.7 The United States Rare Biomarkers Specimen Collection And Stabilization Market
4.2.8 The Canadian Rare Biomarkers Specimen Collection And Stabilization Market
4.2.9 The Mexican Rare Biomarkers Specimen Collection And Stabilization Market
4.3.1 Market by Product: Isolation Kits & Reagents, Blood Collection Tubes, and Systems
4.3.2 Market by Type: Circulating Call Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles
4.3.3 Market by Specimen: Serum/Plasma and Others
4.3.4 Market by Nucleic Acid & Other Biomolecules: RNA, DNA, and Others
4.3.5 Market by Application: NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others
4.3.6 Market by End Use: Research (Research Labs/CROs and Academic Institutes), Diagnostics (Laboratories, Hospitals, and Prenatal Clinic)
4.3.7 The Rare Biomarkers Specimen Collection And Stabilization Market of United Kingdom
4.3.8 The German Rare Biomarkers Specimen Collection And Stabilization Market
4.3.9 The French Rare Biomarkers Specimen Collection And Stabilization Market
4.4.1 Market by Product: Isolation Kits & Reagents, Blood Collection Tubes, and Systems
4.4.2 Market by Type: Circulating Call Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles
4.4.3 Market by Specimen: Serum/Plasma and Others
4.4.4 Market by Nucleic Acid & Other Biomolecules: RNA, DNA, and Others
4.4.5 Market by Application: NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others
4.4.6 Market by End Use: Research (Research Labs/CROs and Academic Institutes), Diagnostics (Laboratories, Hospitals, and Prenatal Clinic)
4.4.7 The Chinese Rare Biomarkers Specimen Collection And Stabilization Market
4.4.8 The Indian Rare Biomarkers Specimen Collection And Stabilization Market
4.4.9 The Japanese Rare Biomarkers Specimen Collection And Stabilization Market
4.5.1 Market by Product: Isolation Kits & Reagents, Blood Collection Tubes, and Systems
4.5.2 Market by Type: Circulating Call Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles
4.5.3 Market by Specimen: Serum/Plasma and Others
4.5.4 Market by Nucleic Acid & Other Biomolecules: RNA, DNA, and Others
4.5.5 Market by Application: NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others
4.5.6 Market by End Use: Research (Research Labs/CROs and Academic Institutes), Diagnostics (Laboratories, Hospitals, and Prenatal Clinic)
4.5.7 Brazilian Rare Biomarkers Specimen Collection And Stabilization Market
7.1.1 Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Product
7.1.2 Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Type
7.1.3 Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Specimen
7.1.4 Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Nucleic Acid & Other Biomolecules
7.1.5 Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Application
7.1.6 Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by End Use
7.1.7 Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Region
Methodology
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.
